Clinical Trial Detail

NCT ID NCT02719015
Title Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Pembrolizumab + rAd-hCD40L

Age Groups: adult

No variant requirements are available.